Ranbaxy Laboratories Limited
Ranbaxy Laboratories Limited is one of the largest companies in India which deals in various segments in terms of pharmaceutical like research, production of wide range of affordable generic drugs and medicines. Due to its best quality pharma products, it has been continuously increasing its customer base in India and across the world. Currently, it has a strong presence in over 23 out of top 25 pharmaceuticals markets worldwide. It has global footprints in 43 countries and its manufacturing facilities in 8 countries which supply medicine in more than 125 countries all-inclusive.
In the year 2008, it signed an agreement with one of the largest Japanese innovator companies that are Daiichi Sankyo Company, for creating of modern generic pharmaceutical powerhouse. Due to that treaty, it came in to top 20 biggest pharmaceuticals companies list. These deal caused company emerged with the great growth and became stronger in terms of its global reach for its capability for drug development.
It is among the few companies which have started its journey in the late 70s and in the year 1994 it has started its world class R&D centre, now, the company has multi-function world class research centre at Gurgaon, India, which dedicated facilities for generics and modern pharmaceuticals research. It has developed various drugs like anti-malarial new drug which has been approved by the Indian Drug Regulator, Drug Controller General of India for marketing as well drug manufacturing in the country. The company has launched drug like Synriam TM, for the treatment of disease Plasmodium Falciparum Malaria and lots other Ranbaxy products. Thus the pharmaceutical company has been continuously involved in research and development.
In the year 2011, its global sales were around US $ 2.1 Bn. Its revenues from emerging markets were around 47 % and from the developing markets were around 46% approximately. Thus it was emerged as a leading company in the drug manufacturing according to 2011 survey.
Ranbaxy is mostly focusing on its generic business in its chief growing markets through organic and inorganic growth routes. Apart from that it also gives more important to its research and development section. For that, company has over 1000 research and development scientists which are continually doing research in the Pharmaceutical field. Its business strategy is to get long term sustainable benefit by its business. So, it is continuously focusing more on its R & D section.
Ranbaxy, the pharmaceuticals company by using its strong R & D techniques and manufacturing facilities is giving its best services by many ways as such manufacturing of generic drugs; value added generic pharmaceuticals, branded generics, active pharmaceuticals, intermediates etc.
It is giving its best performance in Cardiovascular, Respiratory, Dermatology, Orthopaedics, Nutritional, Urology, Central Nervous System etc. So, it shows that company is continuously wired its presence in the operating of Chronic and Lifestyle disease segments. Thus the company has global presence in marketing and manufacturing of drug.
For more information about the company, you can also visit to its website. If you find any query you can contact to its customer care numbers, a friendly team would easily solve your query. If you want direct contact, you can visit to its following address:
Ranbaxy Laboratories Limited
Corporate Office
Plot 90, Sector 32,
Gurgaon -122001 (Haryana), INDIA
Ph: 91- 124- 4135000
Fax: 91-124-4135001
Registered Office
A-41, Industrial Area Phase VIII-A,
SahibzadaAjit Singh Nagar,
Mohali – 160 071 (Punjab), INDIA

Author: Rohit Rao
Rohit Rao is an avid writer, writing content on the topics of varied interests. He works as a content writer in a reputed media house based at Delhi. His professional quality contributes in plenty to promote business online. Rohit is a commerce graduate of Delhi University. He enjoys business writing on topics ranging from loans, finance to insurance. Rohit also maintains a blog of his own.
This author has published 1199 articles so far.